ireland switzerland singapor world leader attract multin
build ex-u manufactur facil biotechnolog therapeut recent
host tour ireland bioproduct facil ge life scienc ge ls technolog
 far pervas label manufactur train center
moreov demand high largest bioprocess facil countri indic
supplier includ ge face deliveri constraint
guid ge ls growth seem low rais estim
believ organ growth rate
bp upsid estim bioprocess biopharma busi
ex-dent repres revenu oper incom
increment growth reiter fair valu buy rate
nibrt tour ge life scienc product everywher ireland
bioproduct tour provid us opportun speak site product
lead countri largest biolog manufactur plant pfe-nr
dublin throughout meet site leader product head note
ge leader product tool like single-us technolog sut howev
leader also note ge vendor struggl keep pace
demand lead time extend dramat view issu
transitori ge renam cytiva integr db oper
model believ pall repres prime case studi db effect anoth
stop brought us nation institut bioprocess research train
nibrt partnership ireland nibrt establish world first pilot-
scale manufactur facil design train research bioprocess
technolog includ ge flex factori tour facil left us
impress addit ge ferment purif media
technolog provid complet front-end fit pall lead posit
conserv ge ls guidanc announc
acquisit ge life scienc set initi guidanc core growth
dig deeper bioproduct market continu view
guidanc extrem conserv base ge life scienc post
revenu growth respect peer buy
rgen-buy srt/dim neutral report double-digit bioprocess growth
cphi industri research group estim demand biolog manufactur
volum increas per annum biolog
trillion global therapeut sale repres
build ge ls aquisit model build ge accret model
gaug manag initi guidanc core growth ep accret
exercis test scenario bear base bull
bear case repres manag guidanc would indic grow
slower industri averag base bull case assum
organ growth drive accret respect
view manag hit target year versu initi guidanc
year manag commentari highlight ge run industry-
lead gross margin versu sartoriu stedim
assum industri averag depreci amort
opex slightli industri averag due impli ebitda margin
initi manag note blend interest increment debt
issu interest rate move favor recent price
initi debt offer bn bn blend rate base
base-cas assumpt view deal model track well ahead initi
valuat attract purchas price ge ls attract
equiti seem under-valued ev/ebitda mulipl around
peer averag bioprocess averag typic life scienc
tool valuat show market place higher valu bioproduct
busi large-cap tool compani valu
ev/ebitda estim howev bioproduct
compani univers averag estim base
deal model industri research purchas prize
opinion bioproduct asset hefti discount ebitda
fair valu reiter fair valu buy rate fv
reach appli multipl ebitda estim
deduct estim debt per share guid
earn accret first year ownership life scienc group
typic valu around ev/ebitda expect bp
annual margin expans faster organ growth drive premium
bioproduct storag servic
sale
sale
interest rate assumpt
sale
sale
bn
million except per share data
impact foreign currenc
total sale
earn jv
management guid cent fx/tariff headwind
